Holen Sie sich die Stockscreener-App
8.92
1.55%
-0.14
Vorhandelsmarkt:
8.97
0.05
+0.56%
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BIOCRYST (BCRX) director Jill Milne granted RSUs and options in board compensation - Stock Titan
BioCryst (BCRX) director receives stock grants and options, updates trust holdings - Stock Titan
BioCryst (BCRX) director receives RSU and option grants under board plan - Stock Titan
BioCryst (BCRX) director Steven Frank awarded RSUs and stock options - Stock Titan
BioCryst (NASDAQ: BCRX) director awarded RSUs and stock options as compensation - Stock Titan
BioCryst (BCRX) director Vincent Milano receives stock and option grants - Stock Titan
BioCryst (BCRX) director receives stock units and options grants - Stock Titan
Biocryst (NASDAQ: BCRX) director receives stock units and options grant - Stock Titan
Biocryst (BCRX) grants Theresa Heggie RSUs and stock options as board pay - Stock Titan
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up (BCRX) - Seeking Alpha
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (NASDAQ: BCRX) investors approve 7M-share stock incentive plan - Stock Titan
Sector Update: Healthcare Stocks Advance Pre-Bell Friday - Moomoo
BioCryst Advances HAE Treatments with New Clinical Data (BCRX) - GuruFocus
BioCryst highlights efficacy gains across hereditary angioedema portfolio - grafa.com
BioCryst presents new data on HAE therapies at EAACI meeting - Investing.com
BioCryst presents new data on HAE therapies at EAACI meeting By Investing.com - Investing.com Canada
Oral HAE drug reduces child attacks; new antibody data across patient subgroups - Stock Titan
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Yahoo Finance
BioCryst Pharmaceuticals Grants Stock Options and RSUs to New Employees - Quiver Quantitative
Nine new BioCryst hires receive stock options, RSUs as inducement - Stock Titan
How Biocryst Pharmaceuticals Inc. (BCRX) Affects Rotational Strategy Timing - Stock Traders Daily
Do BioCryst’s EAACI 2026 HAE Data Plans Subtly Recast the BCRX Long-Term Innovation Story? - Sahm
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances - MarketBeat
BCRX Technical Analysis | Trend, Signals & Chart Patterns | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
Earnings call transcript: BioCryst Q1 2026: EPS Miss, Revenue Beat - Investing.com
BCRX: ORLADEYO and navenibart drive rare disease growth, with key milestones and profitability ahead - TradingView
BIOCRYST (BCRX) Board Chair Vincent Milano receives stock grant as retainer pay - Stock Titan
BioCryst (BCRX) director awarded stock in lieu of cash retainer - Stock Titan
BioCryst (BCRX) director Jill C. Milne receives 1,262-share stock grant as board retainer - Stock Titan
Biocryst (BCRX) director takes share grant instead of cash fee - Stock Titan
BIOCRYST (BCRX) director Steven Frank granted 1,262 shares instead of $11,250 cash - Stock Titan
These 10 mid-cap U.S. healthcare companies rank among the market's most attractively valued stocks - Seeking Alpha
Could BioCryst (BCRX) HAE Data at EAACI Quietly Redefine Its Core Investment Story? - Sahm
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Mixed Returns Temper Its Rare Disease Upside Narrative - Sahm
New ORLADEYO HAE data in children, adults to debut in Istanbul - Stock Titan
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewswire
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
BCRX Should I Buy - Intellectia AI
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
BioCryst director Amy McKee sells $100,284 in company shares - Investing.com UK
BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan
Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):